IBI334-B7H3-hIgG1

EGFR is a tyrosine kinase receptor that plays a vital role in cell proliferation, differentiation, and survival through essential signaling pathways. Abnormal EGFR signaling can cause excessive cell growth and the formation of tumors. Conversely, B7-H3 is an immune checkpoint molecule that primarily inhibits the activation and expansion of T cells, thus preventing an overactive immune response. EGFR/B7-H3 dual antibodies are targeted drugs that specifically target these two molecules. They function by inhibiting EGFR signaling to impede tumor cell proliferation and by blocking B7-H3 signaling to activate T cells, thereby enhancing their ability to attack tumor cells. Consequently, the primary mechanism of action of EGFR/B7-H3 dual antibody therapy is to simultaneously inhibit tumor growth and enhance the immune system's ability to kill, resulting in a dual assault on tumors.